ONCOLYTICS BIOTECH INC 8-K

What Happened
On January 12, 2026, Oncolytics Biotech, Inc. (ONCY) filed an 8-K reporting a press release issued on January 8, 2026 that announced updates to the company’s intellectual property portfolio and ongoing efforts to extend patent protection for its oncolytic drug candidate pelareorep. The filing also attaches a second press release dated January 12, 2026 as exhibits to the report.

Key Details

• Form 8-K filed on January 12, 2026 (Accession No. 0001104659-26-002863).
• Press release dated January 8, 2026 (Exhibit 99.1) announces status updates on IP and patent-extension efforts for pelareorep.
• A second press release dated January 12, 2026 is included as Exhibit 99.2.
• Item reported: 8.01 (Other Events); exhibits listed under Item 9.01.

Why It Matters
Intellectual property protection is critical for a biotech’s ability to commercialize a drug and protect future revenue streams. These updates signal the company is actively pursuing ways to extend exclusivity around pelareorep, which could affect long-term value, licensing potential, or partnership discussions. The 8-K does not report financial results or personnel changes—it's an informational update about IP strategy that investors may want to monitor for future patent decisions or related filings.